RT Journal Article
T1 Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study.
A1 Forouhi, Nita G
A1 Koulman, Albert
A1 Sharp, Stephen J
A1 Imamura, Fumiaki
A1 Kröger, Janine
A1 Schulze, Matthias B
A1 Crowe, Francesca L
A1 Huerta, José María
A1 Guevara, Marcela
A1 Beulens, Joline W J
A1 van Woudenbergh, Geertruida J
A1 Wang, Laura
A1 Summerhill, Keith
A1 Griffin, Julian L
A1 Feskens, Edith J M
A1 Amiano, Pilar
A1 Boeing, Heiner
A1 Clavel-Chapelon, Françoise
A1 Dartois, Laureen
A1 Fagherazzi, Guy
A1 Franks, Paul W
A1 Gonzalez, Carlos
A1 Jakobsen, Marianne Uhre
A1 Kaaks, Rudolf
A1 Key, Timothy J
A1 Khaw, Kay-Tee
A1 Kühn, Tilman
A1 Mattiello, Amalia
A1 Nilsson, Peter M
A1 Overvad, Kim
A1 Pala, Valeria
A1 Palli, Domenico
A1 Quirós, J Ramón
A1 Rolandsson, Olov
A1 Roswall, Nina
A1 Sacerdote, Carlotta
A1 Sanchez-Perez, Maria-Jose
A1 Slimani, Nadia
A1 Spijkerman, Annemieke M W
A1 Tjonneland, Anne
A1 Tormo, Maria-José
A1 Tumino, Rosario
A1 van der A, Daphne L
A1 van der Schouw, Yvonne T
A1 Langenberg, Claudia
A1 Riboli, Elio
A1 Wareham, Nicholas J
K1 Estudios de casos y controles
K1 Diabetes Mellitus tipo 2
K1 Ácidos grasos
K1 Mediana edad
K1 Fosfolípidos
K1 Estudios prospectivos
AB BACKGROUNDConflicting evidence exists regarding the association between saturated fatty acids (SFAs) and type 2 diabetes. In this longitudinal case-cohort study, we aimed to investigate the prospective associations between objectively measured individual plasma phospholipid SFAs and incident type 2 diabetes in EPIC-InterAct participants.METHODSThe EPIC-InterAct case-cohort study includes 12,403 people with incident type 2 diabetes and a representative subcohort of 16,154 individuals who were selected from a cohort of 340.234 European participants with 3·99 million person-years of follow-up (the EPIC study). Incident type 2 diabetes was ascertained until Dec 31, 2007, by a review of several sources of evidence. Gas chromatography was used to measure the distribution of fatty acids in plasma phospholipids (mol%); samples from people with type 2 diabetes and subcohort participants were processed in a random order by centre, and laboratory staff were masked to participant characteristics. We estimated country-specific hazard ratios (HRs) for associations per SD of each SFA with incident type 2 diabetes using Prentice-weighted Cox regression, which is weighted for case-cohort sampling, and pooled our findings using random-effects meta-analysis.FINDINGSSFAs accounted for 46% of total plasma phospholipid fatty acids. In adjusted analyses, different individual SFAs were associated with incident type 2 diabetes in opposing directions. Even-chain SFAs that were measured (14:0 [myristic acid], 16:0 [palmitic acid], and 18:0 [stearic acid]) were positively associated with incident type 2 diabetes (HR [95% CI] per SD difference: myristic acid 1·15 [95% CI 1·09-1·22], palmitic acid 1·26 [1·15-1·37], and stearic acid 1·06 [1·00-1·13]). By contrast, measured odd-chain SFAs (15:0 [pentadecanoic acid] and 17:0 [heptadecanoic acid]) were inversely associated with incident type 2 diabetes (HR [95% CI] per 1 SD difference: 0·79 [0·73-0·85] for pentadecanoic acid and 0·67 [0·63-0·71] for heptadecanoic acid), as were measured longer-chain SFAs (20:0 [arachidic acid], 22:0 [behenic acid], 23:0 [tricosanoic acid], and 24:0 [lignoceric acid]), with HRs ranging from 0·72 to 0·81 (95% CIs ranging between 0·61 and 0·92). Our findings were robust to a range of sensitivity analyses.INTERPRETATIONDifferent individual plasma phospholipid SFAs were associated with incident type 2 diabetes in opposite directions, which suggests that SFAs are not homogeneous in their effects. Our findings emphasise the importance of the recognition of subtypes of these fatty acids. An improved understanding of differences in sources of individual SFAs from dietary intake versus endogenous metabolism is needed.FUNDINGEU FP6 programme, Medical Research Council Epidemiology Unit, Medical Research Council Human Nutrition Research, and Cambridge Lipidomics Biomarker Research Initiative.
PB Elsevier
SN 2213-8587
YR 2014
FD 2014-08-06
LK http://hdl.handle.net/10668/2293
UL http://hdl.handle.net/10668/2293
LA en
NO Forouhi NG, Koulman A, Sharp SJ, Imamura F, Kröger J, Schulze MB, et al. Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study. Lancet Diabetes Endocrinol. 2014; 2(10): 810-8
NO Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 18, 2025